Could TB treatment be cut from 6 months to 17 weeks?
NCT ID NCT05766267
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether two new 17-week drug combinations can treat pulmonary tuberculosis as effectively as the standard 6-month regimen. About 288 people with TB will receive one of three daily pill regimens. The goal is to see if shorter treatment can clear the infection faster and with fewer side effects, potentially making it easier for patients to stick with therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Combination of bedaquiline, moxifloxacin, pyrazinamide, plus either rifabutin or delamanid
What this could lead to
If successful, this could lead to a shorter, 17-week treatment for tuberculosis, making it easier for patients to complete therapy and reduce the spread of the disease.
What could go wrong
This is a mid-stage trial with only 288 participants, so results may not apply to everyone. The shorter regimens might be less effective or cause more side effects than the standard 6-month treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
McGill University Health Centre
Montreal, Canada
-
TBTC Site 09 University of Cape Town Lung Institute (Pty) Ltd
Mowbray, Cape Town, 7700, South Africa
-
TBTC Site 26 Seattle & King County TB Control Program
Seattle, Washington, 98104, United States
-
TBTC Site 30 Uganda-Case Western Reserve Research Collaboration
Kampala, Uganda
-
TBTC Site 45 Les Centres Gheskio (INLR)
Port-au-Prince, Ouest, HT6110, Haiti
-
TBTC Site 67 GHESKIO centers IMIS
Port-au-Prince, Ouest, HT 6124, Haiti
-
TBTC Site 76 CAB-V. Can Tho Province, Vietnam - Thot Not District TB Unit
Can Tho, Can Tho City, 70000, Vietnam
-
Vancouver, British Columbia Centre for Disease Control
Vancouver, Canada